M&A Healthcare Advisors Mid-Year Review Highlights

As we recap the first half of this year, our experience proves that 2023 remains a great time to pursue a sale. Despite overall warnings of an economic slowdown and healthcare M&A reports referencing year-over-year declines as high as 20% (Pitchbook Q2 2023 Global M&A Report, pg. 24), our team has first-hand experience with valuations and multiples remaining consistent with such historic years as 2021 and 2022. The companies we’ve represented (and sold) span a variety of healthcare segments including Pharmacy, Home Health, Home Care, and Physician Practices, with some of our clients reaching multiples as high as 8x Adjusted EBITDA. These transactions have given us the opportunity to work across the table from organizations consisting of LHC Group, CVS, Intermountain Health, and Private Equity. We anticipate, by year end, several more successful transactions including companies providing Hospice, Home Health, Behavioral Health, Primary Care, Staffing, & O&P services.

The upshot is that despite higher levels of uncertainty across the economy, the demand for “quality” healthcare assets remains very consistent. The healthcare network we’ve been able to build & nurture consistently looks to acquire these assets, and we expect them to continue to do so even in the face of volatility in the capital markets.

Below you can find an overview from our client’s describing our representation and value add. Our clients are always willing to speak on our behalf so at the right time, we’re happy to provide references.

We would like to thank all our clients, acquirers, and third parties that contributed to our efforts these last 7 months. We look forward to a fruitful rest of the year for our current client base.